Sign in Pull a receipt

ANRO

Alto Neuroscience, Inc.

Pharmaceuticals · Pharmaceuticals

$124.39 sample

-1.22 (-0.97%) 1D

Market cap

$115.5B

Price as of

2026-10-29

Latest filing

8-K · 2026-10-19

Alerts

8

Price$124.39 +0.64% 3M daily closessample

136.15123.46

2026-08-032026-08-252026-09-162026-10-072026-10-29

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 23INSInsider buy: Director
Oct 19SEC10-Q filed
Oct 13INSInsider sell: Chief Financial Officer
Oct 05INSInsider sell: 10% owner
Sep 24SEC8-K filed: material event
Sep 18INSInsider sell: Chief Executive Officer
Sep 10SECDEF 14A filed
Sep 04INSInsider buy: General Counsel

Sign up to see the real ANRO record →

Company facts

SEC EDGAR registration

Name: Alto Neuroscience, Inc.
Sector: Pharmaceuticals
Industry: Pharmaceuticals
Smart-money score: -5sample, -100 to +100
Reporting currency: USD

Who is positioning in ANRO

sample

Insiders: 25 insider transactions over 90 days, net selling, $174.9M
Congress: 1 members traded over 90 days
Institutions · 13F: 28 funds hold $1.9B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$4.2B +15.1% y/y

Q4 2024Q3 2026

Inventory$2.4B +6.6% y/y

Q4 2024Q3 2026

Accounts receivable$1.9B +6.9% y/y

Q4 2024Q3 2026

Total debt$5.2B +8.8% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $12.4B +11.4% 3M
Sample peer B: $39.7B +0.9% 3M
Sample peer C: $23.0B +1.2% 3M
Sample peer D: $109.9B +4.4% 3M
Sample peer E: $22.7B -11.4% 3M